The emergence of COVID-19 has required people to minimize travel and other daily activities. These limitations have far-reaching consequences on the ability to conduct clinical research studies, which are necessary to advance the development of new medical therapies. To address these constraints, study sponsors have begun to explore modification of protocol-mandated research site visits to allow for telehealth or home visits.
A widely accepted efficacy endpoint for hyperhidrosis studies is the assessment of gravimetric sweat production (GSP).1,2,3,4 The measurements necessary to evaluate GSP are typically performed at a research site on sensitive, non-mobile balances. In anticipation of a possible COVID-related need to perform home-based sweat collection for assessment of primary axillary hyperhidrosis severity, we explored whether transporting specimens affected their weight. For our evaluation, we com-
A widely accepted efficacy endpoint for hyperhidrosis studies is the assessment of gravimetric sweat production (GSP).1,2,3,4 The measurements necessary to evaluate GSP are typically performed at a research site on sensitive, non-mobile balances. In anticipation of a possible COVID-related need to perform home-based sweat collection for assessment of primary axillary hyperhidrosis severity, we explored whether transporting specimens affected their weight. For our evaluation, we com-
